Login Register Cart 0
Generic placeholder image

Current Cancer Therapy Reviews

Editor-in-Chief

ISSN (Print): 1573-3947
ISSN (Online): 1875-6301

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Association of a Genetic Variant in Chromosome 9p21 with Increased Risk of Developing Cervical Cancer

Author(s): Mojde Atabati, Razieh Saber, Parnian Malakuti, Ghazaleh Pourali, Motahareh Heydari-Majd, Pegah Safavi, Mohammad Dashti, Azam Rastgar Moghadam, Farzad Rahmani*, Marjaneh Farazestanian, Negin Behboodi, Mehrane Mehramiz, Mohammadreza Nassiri, Majid Rajabian-Noghondar, Raheleh Rahbarian, Hassan Ramshini, Amirhosein Jafarian, Gordon Ferns, Amir Avan and Malihe Hasanzadeh

Volume 19, Issue 4, 2023

Published on: 11 April, 2023

Page: [358 - 362] Pages: 5

DOI: 10.2174/1573394719666230321153528

Price: $65

Abstract

Background: Cervical cancer is one of the most prevalent gynecologic cancers associated with high morbidity and mortality worldwide. There is mounting evidence indicating an association between the 9p21 locus genetic variants with susceptibility to various human malignancies. In this current study, we aimed to evaluate the potential relationship between the rs1333049 genetic variant in chromosome 9p21 and the risk of cervical carcinogenesis.

Methods: The possible correlation between rs1333049 polymorphism and susceptibility to cervical cancer was investigated in 221 patients with or without cancer. DNAs were isolated and genotyped using a TaqMan-based real-time RT-PCR method.

Results: The rs1333049 genetic variant was found to be correlated with an elevated risk of cervical neoplasia using recessive and additive genetic models (p < 0.001).

Conclusion: Our findings indicated that the CDKN2A/B genetic variant (rs1333049) was significantly associated with an elevated risk of cancer, suggesting its potential as a novel predictive marker for cervical carcinogenesis.

Keywords: Cervical cancer, rs1333049, 9p21, genetic variant, gynecologic cancers, human malignancies.

« Previous Next »
Graphical Abstract

[1]
Rahmani F, Hasanzadeh M, Hassanian SM, et al. Association of a genetic variant in the angiopoietin-like protein 4 gene with cervical cancer. Pathol Res Pract 2020; 216(7): 153011.
[http://dx.doi.org/10.1016/j.prp.2020.153011] [PMID: 32534714]
[2]
Vega Crespo B, Neira VA, Ortíz Segarra J. Barriers and facilitators to cervical cancer screening among under-screened women in Cuenca, Ecuador: the perspectives of women and health professionals. BMC Public Health 2022; 22(1): 2144.
[http://dx.doi.org/10.1186/s12889-022-14601-y] [PMID: 36414955]
[3]
Abdeahad H, Bahrami A, Saeedi N, et al. Association between genetic variants at 9p21 locus with risk of breast cancer: A systematic review and meta-analysis. Pathol Res Pract 2020; 216(7): 152987.
[http://dx.doi.org/10.1016/j.prp.2020.152987] [PMID: 32534702]
[4]
ShahidSales S, Mehramiz M, Ghasemi F, et al. A genetic variant in CDKN2A/B gene is associated with the increased risk of breast cancer. J Clin Lab Anal 2018; 32(1): e22190.
[http://dx.doi.org/10.1002/jcla.22190] [PMID: 28276595]
[5]
Rahmani F, Avan A, Amerizadeh F, Ferns GA, Talebian S, Shahidsales S. The association of a genetic variant in CDKN2A/B gene and the risk of colorectal cancer. EXCLI J 2020; 19: 1316-21.
[PMID: 33122978]
[6]
Ghobadi N, Mehramiz M. ShahidSales S, et al A genetic variant in CDKN2A/2B locus was associated with poor prognosis in patients with esophageal squamous cell carcinoma. J Cell Physiol 2019; 234(4): 5070-6.
[http://dx.doi.org/10.1002/jcp.27310] [PMID: 30238987]
[7]
Congrains A, Kamide K, Ohishi M, Rakugi H. ANRIL: molecular mechanisms and implications in human health. Int J Mol Sci 2013; 14(1): 1278-92.
[http://dx.doi.org/10.3390/ijms14011278] [PMID: 23306151]
[8]
Nielsen NH, Roos G, Emdin SO, Landberg G. Methylation of the p16Ink4a tumor suppressor gene 5′-CpG island in breast cancer. Cancer Lett 2001; 163(1): 59-69.
[http://dx.doi.org/10.1016/S0304-3835(00)00674-1] [PMID: 11163109]
[9]
Kong Y, Hsieh CH, Alonso LC. ANRIL: a lncRNA at the CDKN2A/B locus with roles in cancer and metabolic disease. Front Endocrinol (Lausanne) 2018; 9: 405.
[http://dx.doi.org/10.3389/fendo.2018.00405] [PMID: 30087655]
[10]
Drak Alsibai K, Vacher S, Meseure D, et al. High positive correlations between ANRIL and p16-CDKN2A/p15-CDKN2B/p14-ARF gene cluster overexpression in multi-tumor types suggest deregulated activation of an ANRIL–ARF bidirectional promoter. Noncoding RNA 2019; 5(3): 44.
[http://dx.doi.org/10.3390/ncrna5030044] [PMID: 31438464]
[11]
Li Z, Yu X, Shen J. ANRIL: a pivotal tumor suppressor long non-coding RNA in human cancers. Tumour Biol 2016; 37(5): 5657-61.
[http://dx.doi.org/10.1007/s13277-016-4808-5] [PMID: 26753962]
[12]
Hannou SA, Wouters K, Paumelle R, Staels B. Functional genomics of the CDKN2A/B locus in cardiovascular and metabolic disease: what have we learned from GWASs? Trends Endocrinol Metab 2015; 26(4): 176-84.
[http://dx.doi.org/10.1016/j.tem.2015.01.008] [PMID: 25744911]
[13]
Matheu A, Maraver A, Collado M, et al. Anti-aging activity of the Ink4/Arf locus. Aging Cell 2009; 8(2): 152-61.
[http://dx.doi.org/10.1111/j.1474-9726.2009.00458.x] [PMID: 19239418]
[14]
Lu Y, Zhou X, Xu L, Rong C, Shen C, Bian W. Long noncoding RNA ANRIL could be transactivated by c-Myc and promote tumor progression of non-small-cell lung cancer. OncoTargets Ther 2016; 9: 3077-84.
[PMID: 27307748]
[15]
Seifi S, Pouya F, Rahmani M, et al. Association of cyclin‐dependent kinase inhibitor 2A/B with increased risk of developing breast cancer. J Cell Physiol 2020; 235(6): 5141-5.
[http://dx.doi.org/10.1002/jcp.29388] [PMID: 31721206]
[16]
Qiu JJ, Lin YY, Ding JX, Feng WW, Jin HY, Hua KQ. Long non-coding RNA ANRIL predicts poor prognosis and promotes invasion/metastasis in serous ovarian cancer. Int J Oncol 2015; 46(6): 2497-505.
[http://dx.doi.org/10.3892/ijo.2015.2943] [PMID: 25845387]
[17]
Sun Z, Ou C, Ren W, Xie X, Li X, Li G. Downregulation of long non-coding RNA ANRIL suppresses lymphangiogenesis and lymphatic metastasis in colorectal cancer. Oncotarget 2016; 7(30): 47536-55.
[http://dx.doi.org/10.18632/oncotarget.9868] [PMID: 27286457]
[18]
Wan G, Mathur R, Hu X, et al. Long non-coding RNA ANRIL (CDKN2B-AS) is induced by the ATM-E2F1 signaling pathway. Cell Signal 2013; 25(5): 1086-95.
[http://dx.doi.org/10.1016/j.cellsig.2013.02.006] [PMID: 23416462]
[19]
Kotake Y, Nakagawa T, Kitagawa K, et al. Long non-coding RNA ANRIL is required for the PRC2 recruitment to and silencing of p15INK4B tumor suppressor gene. Oncogene 2011; 30(16): 1956-62.
[http://dx.doi.org/10.1038/onc.2010.568] [PMID: 21151178]
[20]
Nie F, Sun M, Yang J, et al. Long noncoding RNA ANRIL promotes non-small cell lung cancer cell proliferation and inhibits apoptosis by silencing KLF2 and P21 expression. Mol Cancer Ther 2015; 14(1): 268-77.
[http://dx.doi.org/10.1158/1535-7163.MCT-14-0492] [PMID: 25504755]
[21]
Zhang E, Kong R, Yin D, et al. Long noncoding RNA ANRIL indicates a poor prognosis of gastric cancer and promotes tumor growth by epigenetically silencing of miR-99a/miR-449a. Oncotarget 2014; 5(8): 2276-92.
[http://dx.doi.org/10.18632/oncotarget.1902] [PMID: 24810364]
[22]
Congrains A, Kamide K, Katsuya T, et al. CVD-associated non-coding RNA, ANRIL, modulates expression of atherogenic pathways in VSMC. Biochem Biophys Res Commun 2012; 419(4): 612-6.
[http://dx.doi.org/10.1016/j.bbrc.2012.02.050] [PMID: 22382030]
[23]
Zhang Z, Feng L, Liu P, Duan W. ANRIL promotes chemoresistance via disturbing expression of ABCC1 by regulating the expression of Let-7a in colorectal cancer. Biosci Rep 2018; 38(6): BSR20180620.
[http://dx.doi.org/10.1042/BSR20180620] [PMID: 30279206]
[24]
Li WQ, Pfeiffer RM, Hyland PL, et al. Genetic polymorphisms in the 9p21 region associated with risk of multiple cancers. Carcinogenesis 2014; 35(12): 2698-705.
[http://dx.doi.org/10.1093/carcin/bgu203] [PMID: 25239644]
[25]
Gu F, Pfeiffer RM, Bhattacharjee S, et al. Common genetic variants in the 9p21 region and their associations with multiple tumours. Br J Cancer 2013; 108(6): 1378-86.
[http://dx.doi.org/10.1038/bjc.2013.7] [PMID: 23361049]
[26]
Lebok P, Roming M, Kluth M, et al. p16 overexpression and 9p21 deletion are linked to unfavorable tumor phenotype in breast cancer. Oncotarget 2016; 7(49): 81322-31.
[http://dx.doi.org/10.18632/oncotarget.13227] [PMID: 27835607]
[27]
Royds JA, Pilbrow AP, Ahn A, et al. The rs11515 polymorphism is more frequent and associated with aggressive breast tumors with increased ANRIL and decreased p16 INK4a expression. Front Oncol 2016; 5: 306.
[http://dx.doi.org/10.3389/fonc.2015.00306] [PMID: 26835415]
[28]
Thakur N, Hussain S, Nasare V, Das BC, Basir SF, Bharadwaj M. Association analysis of p16 (CDKN2A) and RB1 polymorphisms with susceptibility to cervical cancer in Indian population. Mol Biol Rep 2012; 39(1): 407-14.
[http://dx.doi.org/10.1007/s11033-011-0752-z] [PMID: 21567202]

Rights & Permissions Print Cite
Article Metrics
22
3
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy